St. Jude Medical (STJ) Presents Significant Data for TAVI Tech, AMPLATZER Cardiac Plug
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Join SI Premium – FREE
St. Jude Medical, Inc. (NYSE: STJ), reports that significant clinical data for its structural heart portfolio is being presented during EuroPCR. Among the highlights are first-in-man and six-month data for the company’s Portico™ Transcatheter Aortic Heart Valve and results from a multicenter study for AMPLATZER™ Cardiac Plug (ACP) technology.
St. Jude Medical’s Transcatheter Aortic Valve Implantation (TAVI) Technology
Information about the St. Jude Medical Portico valve will be presented during a Glimpse of the Future session on Friday, May 18 from 9:00 to 12:00 in the Maillot Room. The Emerging Technologies for Transcatheter Aortic Valve Therapies session will include a pre-recorded live case using the St. Jude Medical Portico valve, and present six-month data from the first-in-man experience by Dr. Ganesh Manoharan of Royal Victoria Hospital in Belfast, U.K.
The primary endpoint for patients in the five-center study is 30-day, all-cause mortality with secondary safety and effectiveness endpoints; patients will be followed for one year. The technology remains on track for a limited European launch in 2012. It is not approved in the United States.
AMPLATZER Cardiac Plug Data
Results from the AMPLATZER Cardiac Plug European Post-Market Observational Study will be presented in several sessions during EuroPCR.
The ACP was designed to close the Left Atrial Appendage (LAA), a tubular-shaped, muscular pouch connected to the atrium of the heart. The ACP is intended for patients diagnosed with non-valvular atrial fibrillation (AF) to help prevent blood clots from forming in the heart and may lessen the risk of stroke. During episodes of AF, atrial contractions are rapid and irregular, which pools blood in the LAA and increases the likelihood of a clot to form. If a clot is released from the LAA, it can enter circulation and potentially cause a stroke.
The prospective, observational study is a non-randomized evaluation of 204 patients treated at 15 European investigative centers to assess closure and adverse event rates associated with the ACP for LAA closure. The multicenter study enrolled patients with a history of paroxysmal, persistent or permanent nonvalvular AF implanted with the ACP.
A late-breaking trial session on Interventions for Structural Heart Disease will take place on Thursday, May 17, from 15:00 to 16:20 in Room 241. During the session, Left Atrial Appendage Closure with the ACP: Results of the European Post-Market Observational Study will be presented by Dr. Kevin Walsh, cardiologist at the Mater Misericordiae University Hospital in Dublin, Ireland.
St. Jude Medical’s Transcatheter Aortic Valve Implantation (TAVI) Technology
Information about the St. Jude Medical Portico valve will be presented during a Glimpse of the Future session on Friday, May 18 from 9:00 to 12:00 in the Maillot Room. The Emerging Technologies for Transcatheter Aortic Valve Therapies session will include a pre-recorded live case using the St. Jude Medical Portico valve, and present six-month data from the first-in-man experience by Dr. Ganesh Manoharan of Royal Victoria Hospital in Belfast, U.K.
The primary endpoint for patients in the five-center study is 30-day, all-cause mortality with secondary safety and effectiveness endpoints; patients will be followed for one year. The technology remains on track for a limited European launch in 2012. It is not approved in the United States.
AMPLATZER Cardiac Plug Data
Results from the AMPLATZER Cardiac Plug European Post-Market Observational Study will be presented in several sessions during EuroPCR.
The ACP was designed to close the Left Atrial Appendage (LAA), a tubular-shaped, muscular pouch connected to the atrium of the heart. The ACP is intended for patients diagnosed with non-valvular atrial fibrillation (AF) to help prevent blood clots from forming in the heart and may lessen the risk of stroke. During episodes of AF, atrial contractions are rapid and irregular, which pools blood in the LAA and increases the likelihood of a clot to form. If a clot is released from the LAA, it can enter circulation and potentially cause a stroke.
The prospective, observational study is a non-randomized evaluation of 204 patients treated at 15 European investigative centers to assess closure and adverse event rates associated with the ACP for LAA closure. The multicenter study enrolled patients with a history of paroxysmal, persistent or permanent nonvalvular AF implanted with the ACP.
A late-breaking trial session on Interventions for Structural Heart Disease will take place on Thursday, May 17, from 15:00 to 16:20 in Room 241. During the session, Left Atrial Appendage Closure with the ACP: Results of the European Post-Market Observational Study will be presented by Dr. Kevin Walsh, cardiologist at the Mater Misericordiae University Hospital in Dublin, Ireland.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Solowin Holdings marks 10 years, expands into stablecoins and AI
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
